Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see ). This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. ) accepts responsibility for the adequacy or accuracy of this release. Nor its Regulation Services Provider (as that term is defined in the policies of the Has in no way passed upon the merits of the Company has neither approved nor disapproved the contents of this press release. For further information, please refer to Company's website at or its introductory video The TSX Venture Exchange Inc. Although the focus of the Company is currently breast cancer, it recognizes that upon further proof of concept, its technology may be applicable to such other cancers as well. approved protocol has provision to allow testing the vaccine in selected patients with other cancers as well, including prostate, ovarian, pancreas, lung and bladder cancers among others. The Company is planning to advance its cancer immunotherapy technology in an FDA Phase I/II clinical trial with up to 24 breast cancer patients with advanced stages of solid tumors. Again, results were seen rapidly and with little to no adverse side effects. This result was the most unique finding, given that the brain is largely considered an untouchable site in terms of cancer regression. In one patient, cancer regressed in all sites to which the cancer had spread, including lesions in the breast, lung, and even brain. The results were targeted, with little to no side effects, and were achieved rapidly, with regression occurring within 6 weeks. In some cases, the lifespan was five times longer expected. Most uniquely, BriaCell has achieved these results in patients who had prior failed all other available therapies including various kinds of chemotherapy. The results of two FDA Phase I clinical trials have been encouraging in terms of both safety and efficacy in patients with advanced, stage-IV breast cancer. The Company has demonstrated unique and unprecedented results, and is intent on building upon these results to further advance BriaVax™ through the FDA Clinical Trials in order to help cancer patients with no other options. This approach is also more likely to prevent recurrence and is not expected to produce the serious side effects seen with chemotherapy. Immunotherapies are believed to be a more targeted, less toxic approach to managing cancer. Immunotherapies have come to the forefront of the fight against cancer, because they harness the body's own immune system in recognizing and selectively destroying the cancer cells, sparing normal ones. ABOUT BRIACELLīriaCell is a breast cancer immunotherapy biotechnology company. , where he specialized in Pharmacology, and he is the named inventor on patents in the cell-therapy and oncology fields. Is responsible for awarding the Nobel Prize in Physiology or Medicine. Was recently ranked amongst the top-10 medical universities in the world, and its famed , where he focused on Molecular Neurobiology and developed technologies which led to 6 patent applications. DuringĪcademic career, he was an Associate Professor for nearly 5 years at the BriaCell Therapeutics : Announces New President, CEO and Chairman of the Boardīecame Vice President of Neuronyx, responsible for its Cell Therapy division.
0 Comments
Leave a Reply. |